World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
18096
World Ranking
15824
National Ranking
7963

Susan M. Blaney publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Susan M. Blaney sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 305 publications — 18th percentile

18% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Susan M. Blaney D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Susan M. Blaney sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Susan M. Blaney is affiliated with Baylor College of Medicine in the United States. Their research contributions primarily span the fields of medicine and biochemistry, genetics, and molecular biology. Specific subfields include molecular biology, oncology, genetics, neurology, and pulmonary and respiratory medicine.

The main topics of Blaney's research involve neuroblastoma research and treatments, glioma diagnosis and treatment, cancer therapeutics and mechanisms, histone deacetylase inhibitors research, lung cancer treatments and mutations, cancer, hypoxia, and metabolism, as well as genomics and chromatin dynamics.

Their recent publications demonstrate an active role in cancer research, particularly pediatric cancers and brain tumors. Notable papers include:

  • Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912), 2021, Clinical Cancer Research
  • ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma, 2021, Cancer Discovery
  • A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study, 2020, Neuro-Oncology
  • A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma, 2020, Pediatric Blood & Cancer
  • Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report, 2021, Neuro-Oncology

Blaney frequently collaborates with several researchers, including Brenda J. Weigel, Charles G. Minard, Frank M. Balis, Elizabeth Fox, and Peter C. Adamson. These collaborations reflect a multidisciplinary approach to cancer and brain tumor research.

The venues where Blaney has published recurrently include Neuro-Oncology, Clinical Cancer Research, Cancer Discovery, Pediatric Blood & Cancer, and the Journal of Clinical Oncology. These venues align with their focus on oncology and brain tumor research.

Best Publications

  • Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

    Yael P Mossé;Megan S Lim;Stephan D Voss;Keith Wilner

  • Atypical Teratoid/Rhabdoid Tumors (ATRT): Improved Survival in Children 3 Years of Age and Older With Radiation Therapy and High-Dose Alkylator-Based Chemotherapy

    Tanya M. Tekautz;Christine E. Fuller;Susan Blaney;Maryam Fouladi

  • Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma

    Ching-Hon Pui;Hazem H. Mahmoud;Joseph M. Wiley;Gerald M. Woods

  • Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.

    Yael P. Mossé;Stephan D. Voss;Megan S. Lim;Delphine Rolland

  • Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children’s Oncology Group

    Stacey L. Berg;Susan M. Blaney;Meenakshi Devidas;Tom A. Lampkin

  • Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop.

    Roger J. Packer;Jaclyn A. Biegel;Susan Blaney;Jonathan Finlay

  • Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study

    Julia L. Glade Bender;Peter C. Adamson;Joel M. Reid;Lu Xu

  • Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC

    Xiao Nan Li;Qin Shu;Jack Men Feng Su;Laszlo Perlaky

  • Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study.

    Martin A. Champagne;Renaud Capdeville;Mark Krailo;Wenchun Qu

  • Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study

    Elizabeth A. Raetz;Mitchell S. Cairo;Michael J. Borowitz;Susan M. Blaney

  • A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.

    Mason Bond;Mark L. Bernstein;Alberto Pappo;Kirk R. Schultz

  • Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines.

    Ronald J. Bernardi;Amanda R. Lowery;Patrick A. Thompson;Susan M. Blaney

  • Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial.

    Sima Jeha;H. Kantarjian;D. Irwin;V. Shen

  • Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group

    Suman Malempati;Brenda Weigel;Ashish M. Ingle;Charlotte H. Ahern

  • Expression Analysis of Juvenile Pilocytic Astrocytomas by Oligonucleotide Microarray Reveals Two Potential Subgroups

    Kwong Kwok Wong;Yi Mieng Chang;Yvonne T M Tsang;Laszlo Perlaky

  • Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report

    Maryam Fouladi;Julie R. Park;Clinton F. Stewart;Richard J. Gilbertson

  • Phase I Trial and Pharmacokinetic Study of the Farnesyltransferase Inhibitor Tipifarnib in Children With Refractory Solid Tumors or Neurofibromatosis Type I and Plexiform Neurofibromas

    Brigitte C. Widemann;Wanda L. Salzer;Robert J. Arceci;Susan M. Blaney

  • Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.

    Ian F. Pollack;Regina I. Jakacki;Susan M. Blaney;Michael L. Hancock

  • Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward

    Joanne P. Lagmay;Mark D. Krailo;Ha Dang;Ae Rang Kim

  • Bortezomib interactions with chemotherapy agents in acute leukemia in vitro

    Terzah M. Horton;Anurhadha Gannavarapu;Susan M. Blaney;David Z. D’Argenio

Frequent Co-Authors

Peter C. Adamson
Peter C. Adamson Children's Hospital of Philadelphia
Mark Krailo
Mark Krailo University of Southern California
Frank M. Balis
Frank M. Balis Children's Hospital of Philadelphia
Larry E. Kun
Larry E. Kun St. Jude Children's Research Hospital
James M. Boyett
James M. Boyett St. Jude Children's Research Hospital
Roger J. Packer
Roger J. Packer Children’s National Health System
Clinton F. Stewart
Clinton F. Stewart St. Jude Children's Research Hospital
Ian F. Pollack
Ian F. Pollack University of Pittsburgh
Richard J. Gilbertson
Richard J. Gilbertson University of Cambridge
David G. Poplack
David G. Poplack Baylor College of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degree programs in healthcare opens new doors for students and working professionals alike. One common concern is how much is online nursing school; tuition costs vary but many programs offer affordable paths compared to traditional on-campus routes.

For registered nurses aiming to advance, cheapest online rn to bsn programs allow for greater flexibility and career growth. These programs help RNs earn a Bachelor of Science in Nursing entirely online, often in an accelerated format and at a lower cost.

Those seeking leadership, teaching, or research roles may consider a phd in nursing online programs. Such programs offer rigorous academic training and open doors to advanced healthcare careers without interrupting current work schedules.

Additionally, direct entry msn programs for non nurses online are an ideal option for individuals with non-nursing bachelor’s degrees who want to quickly transition into advanced nursing practice.

Exploring these online pathways ensures more accessible, flexible opportunities to build a rewarding career in medicine and healthcare.

Best Scientists Citing Susan M. Blaney

Trending Scientists

Recently Published Articles